Immuneering (IMRX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswireNov 27 08:00 ET
Mizuho Securities Maintains Immuneering(IMRX.US) With Buy Rating, Announces Target Price $8
Moomoo NewsNov 25 18:31 ET · Ratings
Immuneering Price Target Maintained With a $13.00/Share by Chardan Capital
Dow JonesNov 20 18:04 ET · Ratings
Immuneering Is Maintained at Buy by Chardan Capital
Dow JonesNov 20 18:04 ET · Ratings
Immuneering Corp. Reports Q3 Loss, Highlights Progress
TipRanksNov 15 22:54 ET
Immuneering GAAP EPS of -$0.49
Seeking AlphaNov 14 10:14 ET

Comments

Teddy123

Nov 27 08:21

Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference

$Immuneering (IMRX.US)$
27/11/2024 - 22:00
CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference, which is taking place at the Lotte New York Pa...

Trytosaveabit

Nov 20 17:28

Upcoming possible catalysts! WATCHING!

$Immuneering (IMRX.US)$ Near-Term Milestone Expectations
IMM-1-104
•Initial data from at least one additional arm of the Phase 2a portion of the Company’s Phase 1/2a trial is expected by year end.
IMM-6-415
•Initial PK, PD and safety data from the Phase 1 portion of the Company’s Phase 1/2a trial is expected by year end.

1

Teddy123

Nov 14 05:39

Immuneering Reports Third Quarter 2024 Financial Results and Provides Business Updates

$Immuneering (IMRX.US)$
14/11/2024 - 05:05
- Announced Positive Initial Data, Including Complete and Partial Responses, with IMM-1-104 in Combination with Chemotherapy in First-Line Pancreatic Cancer Patients -
Granted FDA Orphan Drug Designation for IMM-1-104 in the Treatment of Pancreatic Cancer and Fast Track Designation in First-line Pancreatic Cancer
Initial Data From At Least One Additional Arm of the Ph...

1

我要向钱看

Nov 13 16:36

CONTINUE FROM PREVIOUS UPDATES

$Immuneering (IMRX.US)$ Immuneering: Expects Cash Runway to Be Sufficient to Fund Ops Into 4Q 2025 >IMRX

1

我要向钱看

Nov 13 15:25

UPDATES

$Immuneering (IMRX.US)$ Immuneering (NASDAQ:IMRX) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.56) by 12.5 percent.

IMRX Immuneering

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target